Top

American Journal of Clinical Dermatology

Published in:

01-04-2016 | Review Article

Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit

Authors: Christine Blome, Marc A. Radtke, Leah Eissing, Matthias Augustin

Published in: American Journal of Clinical Dermatology | Issue 2/2016

Abstract

Health-related quality of life (HRQoL) is often markedly impaired in both adults and children with atopic dermatitis. The quality of life of the parents of infants or children with this chronic disease is also affected owing to problems such as itch-induced sleeping problems and treatment effort. As HRQoL is only partly associated with disease severity, both parameters should be evaluated in research and clinical practice. For the measurement of HRQoL, both skin- and disease-specific questionnaires are available in addition to generic instruments. In randomized controlled trials on atopic dermatitis, HRQoL is most commonly evaluated with the Dermatology Life Quality Index for use in adults and related questionnaires for children and families, such as the Children’s Dermatology Life Quality Index. There is evidence that different treatment modalities may be effective in improving HRQoL in adults, children, and parents, which is supported by the patients’ own evaluation of treatment benefit in an observational study.

Bullinger M. Assessing health related quality of life in medicine: an overview over concepts, methods and applications in international research. Restor Neurol Neurosci. 2002;20:93–101.PubMed

Schafer I, Hacker J, Rustenbach SJ, et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010;20:62–7. doi:10.1684/ejd.2010.0815.PubMed

Maksimovic N, Jankovic S, Marinkovic J, et al. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39:42–7. doi:10.1111/j.1346-8138.2011.01295.x.CrossRefPubMed

Langenbruch A, Radtke M, Franzke N, et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol. 2014;28:719–26. doi:10.1111/jdv.12154.CrossRefPubMed

van Valburg, Rosalinda W C, Willemsen MG, et al. Quality of life measurement and its relationship to disease severity in children with atopic dermatitis in general practice. Acta Derm Venereol. 2011;91:147–51. doi:10.2340/00015555-1026.

Blome C, Augustin M, Siepmann D, et al. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol. 2009;161:1143–8. doi:10.1111/j.1365-2133.2009.09328.x.CrossRefPubMed

Basra MKA, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997–1035. doi:10.1111/j.1365-2133.2008.08832.x.PubMed

Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140:1513–9. doi:10.1001/archderm.140.12.1513.CrossRefPubMed

Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi:10.1159/000370220.CrossRefPubMed

10.

Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;41:151–8.CrossRefPubMed

11.

Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430–4.CrossRefPubMed

12.

Beikert FC, Langenbruch AK, Radtke MA, et al. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306:279–86. doi:10.1007/s00403-013-1402-1.CrossRefPubMed

13.

Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215:123–9. doi:10.1159/000104263.CrossRefPubMed

14.

Ricci G, Bendandi B, Bellini F, et al. Atopic dermatitis: quality of life of young Italian children and their families and correlation with severity score. Pediatr Allergy Immunol. 2007;18:245–9. doi:10.1111/j.1399-3038.2006.00502.x.CrossRefPubMed

15.

Chamlin SL, Frieden IJ, Williams ML, et al. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114:607–11. doi:10.1542/peds.2004-0374.CrossRefPubMed

16.

Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428–33. doi:10.1016/j.jaci.2012.10.041.CrossRefPubMedPubMedCentral

17.

Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128:668–71. doi:10.1016/j.jaci.2011.05.003.CrossRefPubMedPubMedCentral

18.

Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155:145–51. doi:10.1111/j.1365-2133.2006.07185.x.CrossRefPubMed

19.

Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22:192–9. doi:10.1111/j.1525-1470.2005.22303.x.CrossRefPubMed

20.

Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984–92. doi:10.1111/j.1742-1241.2006.01047.x.CrossRefPubMed

21.

Mozaffari H, Pourpak Z, Pourseyed S, et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect. 2007;40:260–4.PubMed

22.

Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed

23.

Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942–9.CrossRefPubMed

24.

Holme SA, Man I, Sharpe JL, et al. The Children’s Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol. 2003;148:285–90.CrossRefPubMed

25.

Basra MKA, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156:528–38. doi:10.1111/j.1365-2133.2006.07617.x.CrossRefPubMed

26.

Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol. 2004;150:274–83.CrossRefPubMed

27.

Basra MKA, Gada V, Ungaro S, et al. Infants’ Dermatitis Quality of Life Index: a decade of experience of validation and clinical application. Br J Dermatol. 2013;169:760–8. doi:10.1111/bjd.12563.CrossRefPubMed

28.

Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134:800–7. doi:10.1016/j.jaci.2014.07.043.CrossRefPubMed

29.

Home IV Meeting. Harmonising outcome measures for eczema. Available from: http://www.nottingham.ac.uk/homeforeczema/documents/home-iv-meeting-minutes.pdf. Accessed 12 Jan 2016.

30.

Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011;6:e17520. doi:10.1371/journal.pone.0017520.CrossRefPubMedPubMedCentral

31.

McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006;20:248–54. doi:10.1111/j.1468-3083.2006.01383.x.CrossRefPubMed

32.

Staab D, Kaufmann R, Brautigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1 % improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16:527–33. doi:10.1111/j.1399-3038.2005.00306.x.CrossRefPubMed

33.

Janmohamed SR, Oranje AP, Devillers AC, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2014;70:1076–82. doi:10.1016/j.jaad.2014.01.898.CrossRefPubMed

34.

Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839–46. doi:10.1016/S0140-6736(06)68340-2.CrossRefPubMed

35.

Hon KLE, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2007;157:357–63. doi:10.1111/j.1365-2133.2007.07941.x.CrossRefPubMed

36.

Drago L, Iemoli E, Rodighiero V, et al. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol. 2011;24:1037–48.PubMed

37.

Drago L, Toscano M, de Vecchi E, et al. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin Gastroenterol. 2012;46(Suppl):S56–63. doi:10.1097/MCG.0b013e318265ef38.CrossRefPubMed

38.

Matsumoto M, Ebata T, Hirooka J, et al. Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2014;113:209–216.e7; doi:10.1016/j.anai.2014.05.002.

39.

Gerasimov SV, Vasjuta VV, Myhovych OO, et al. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol. 2010;11:351–61. doi:10.2165/11531420-000000000-00000.CrossRefPubMed

40.

Byremo G, Rod G, Carlsen KH. Effect of climatic change in children with atopic eczema. Allergy. 2006;61:1403–10. doi:10.1111/j.1398-9995.2006.01209.x.CrossRefPubMed

41.

Grillo M, Gassner L, Marshman G, et al. Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol. 2006;23:428–36. doi:10.1111/j.1525-1470.2006.00277.x.CrossRefPubMed

42.

Weber MB, de Fontes Neto P, da Luz Tarso, Prati C, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. J Eur Acad Dermatol Venereol. 2008;22:992–7. doi:10.1111/j.1468-3083.2008.02697.x.CrossRefPubMed

43.

Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332:933–8. doi:10.1136/bmj.332.7547.933.CrossRefPubMedPubMedCentral

44.

Ersser SJ, Latter S, Sibley A, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2007;(3):CD004054. doi:10.1002/14651858.CD004054.pub2.

45.

Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18:110–5. doi:10.1016/j.jval.2014.10.007.CrossRefPubMed

46.

Steinke S, Langenbruch A, Stander S, et al. Therapeutic benefits in atopic dermatitis care from the patients’ perspective: results of the German national health care study ‘Atopic Health’. Dermatology. 2014;228:350–9. doi:10.1159/000358587.CrossRefPubMed

47.

Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301:561–71. doi:10.1007/s00403-009-0928-8.CrossRefPubMed

Title: Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit
Authors: Christine Blome
Marc A. Radtke
Leah Eissing
Matthias Augustin
Publication date: 01-04-2016
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 2/2016
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-015-0171-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Reply to Fluegge: Association Between Atopic Dermatitis and Autism Spectrum Disorders: A Systematic Review

Coffee Consumption and Melanoma: A Systematic Review and Meta-Analysis of Observational Studies

Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment

Comment on: “Association between Atopic Dermatitis and Autism Spectrum Disorders: A Systematic Review”

Combination Therapies for Melanoma: A New Standard of Care?

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?